Hi [[ session.user.profile.firstName ]]

Forensic Science

  • Disruptive forces in technology and the implications for healthcare
    Disruptive forces in technology and the implications for healthcare Fonny Schenck (CEO Across Health) Recorded: Apr 4 2017 45 mins
    Live Webinar on April 4 at 5pm CET
    Life Sciences is an industry full of established, large companies with significant barriers to entry and often long legacies of success. But the weather is changing – and the structures and strategies which have kept these enterprises safe may soon become liabilities. What is only just becoming clear, though, is how fast this is happening. Along all key areas of the value chain, new & nimble competitors are entering the scene - and they are playing a totally different game.

    Find out more about these disruptive trends, get the highlights of our second ‘Healthcare Disruption Tour’, which went to the heart of the action in Jan 2017, and learn why pharma should take note…and how it can best prepare & organize for this tsunami.

    Topics:
    • Key trends in healthcare disruption
    • Impressions from the second healthcare disruption tour
    • Embedding disruption in pharma organisations
  • Sanger Arrayed CRISPR Screening in partnership with Evotec
    Sanger Arrayed CRISPR Screening in partnership with Evotec Dr. Hauke Cornils-Res Scientist, Evotec & Shawn Shafer-Dir. Advance Genomics Life Science Business of Merck KGaA, Darmstadt, Recorded: Mar 16 2017 50 mins
    CRISPR Cas9 nucleases have revolutionized the field of gene editing and high-throughput lentiviral screens continue to hold ever-increasing promise for both basic research and development of future therapies to benefit human health. Even with such powerful technologies at hand, researchers new to the field may find the screening of multiple targets to be challenging and time-consuming. This webinar discusses the Evotec partnership with Life Science Business of Merck KGaA, Darmstadt, Germany and the screening services for drug discovery.
  • Approval and access: Overcoming the final hurdle of drug development
    Approval and access: Overcoming the final hurdle of drug development Professor Luca Pani, University of Miami, Angelika Joos,MSD (Europe) Inc. Ana Palma, Sobi, Belgium Recorded: Mar 10 2017 61 mins
    2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.

    With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?

    pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.

    Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
    Topics up for discussion include:
    •Integrating HTA and regulatory strategy – the best way forward
    •Regional variation and implication – how to efficiently and effectively navigate EU market access
    •Proving value – how to leverage real world evidence to meet increasing demands for observational data
    •Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively
  • How do you Decide Whom to Biopsy for Prostate Cancer?
    How do you Decide Whom to Biopsy for Prostate Cancer? Dr. E. David Crawford Recorded: Feb 17 2017 61 mins
    In our webinar, Identifying Men with Prostate Cancer—The Role of phi and Other Biomarkers, Dr. E. David Crawford will discuss key issues that challenge a physician's ability to make informed decisions regarding whom to biopsy for prostate cancer. After the webinar, you will be able to:

    • Understand the historical perspective and controversy regarding prostate-specific antigen (PSA) screening

    • Improve your interpretation of a PSA result

    • Use biomarkers, such as Prostate Health Index (phi), to reduce negative biopsies and have more confidence in the decision to biopsy

    • Understand how the phi score, combined with family and patient history, can determine patient management decisions

    Dr. Crawford is an internationally renowned urologist and distinguished endowed professor of surgery, urology and radiation oncology. He also serves as the head of the section of urologic oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
  • Achieve Better Hematology Quality Control with Bulls X̄B
    Achieve Better Hematology Quality Control with Bulls X̄B Dr. Guido Vranken and Lobke Tremmerie Recorded: Dec 13 2016 50 mins
    In this webinar, Dr. Guido Vranken and product manager Lobke Tremmerie discuss how to implement Bulls XB algorithm, which uses RBC indices to create a weighted moving average of patient sample results, to statistically monitor hematology results. This unique algorithm, offered on Beckman Coulter hematology instruments, allows users to monitor result quality with no additional reagents, software licenses or costs. Laboratories worldwide can implement this simple, powerful tool to enhance results and improve compliance. P.A.C.E. credit is available for your participation.*

    Dr. Guido Vranken has been working with customers for over 30 years across different disciplines, including protein chemistry, immunoassay and hematology. He specializes in conducting internal and external validation studies. Dr. Vranken spent three years as a lecturer on statistics at the University of Ghent.

    Lobke Tremmerie earned her environmental engineering degree from the University of Ghent in 2002. She first became an electrophoresis and nephelometry sales engineer at Analis, Beckman Coulter’s exclusive Belgian distributor. Following her true passion, she transferred into the hematology division in 2004. Ms. Tremmerie currently serves as Analis’ cellular biology product marketing manager.
  • Taking health wearables to the next level – where is the market heading?
    Taking health wearables to the next level – where is the market heading? Roberto Slepetys, Martin Pöhlchen, Gayatri Gopal, Andrew McConaghie Recorded: Dec 8 2016 63 mins
    With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
    In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
    – The user perspective: perception, adoption and expectations today and tomorrow
    – The technology perspective: biggest successes and most room for improvements
    – The societal and regulatory perspective: cost and risks versus benefits and opportunities
  • Adjusting Data Parameters to Improve Results and Workflow
    Adjusting Data Parameters to Improve Results and Workflow Dr. Michael Samoszuk Recorded: Dec 7 2016 18 mins
    In this webinar, Dr. Michael Samoszuk discusses the correlative relationships between urine chemistry analytes and the particles noted under the microscope. Attendees will learn how using the knowledge of these correlations can optimize parameter setting for improved laboratory workflow.
  • The hepatitis C conundrum: balancing cost and affordability
    The hepatitis C conundrum: balancing cost and affordability Ashley Pitcher, Natasha Martin, Paul Tunnah Recorded: Nov 22 2016 68 mins
    Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.

    Key topics to be discussed include:
    – The burden of HCV
    – The current market landscape
    – The current patient access model and its impact on budget
    – Cost efficiencies shown by modelling
    – Cure versus lifetime treatment costs
  • Red Blood Cell Data Correlation Between Urinalysis Methods
    Red Blood Cell Data Correlation Between Urinalysis Methods Dr. Michael Samoszuk Recorded: Nov 16 2016 21 mins
    In this webinar, Dr. Michael Samoszuk will discuss how red blood cell data reported from urine chemistry test strip analysis can correlate to red blood cell data gathered from the microscope, even when the data appears to be conflicting. Attendees will discover some of the underlying factors that could cause this to occur and learn how to minimize reporting inconclusive or inaccurate results.
  • SygRNA™-Synthetic Two Part CRISPR RNA system
    SygRNA™-Synthetic Two Part CRISPR RNA system Dr. Gurpreet Singh Balrey- Global Technical Applications Manager at Merck Recorded: Nov 16 2016 58 mins
    The CRISPR/Cas genome editing system has revolutionized almost every aspect of the life science industry. Until recently, the most used formats for this technology have been plasmids, mRNA, or lentivirus. Each reagent has been successful in its own right, however, each approach has limitations. SygRNATM, the two-part synthetic crRNA and tracrRNA, increases the pace of research, decreases costs, and can be used with Cas9 protein, Cas9 mRNA and Cas9 expressing cells/models.

    This webinar discusses the development of the SygRNATM system, protocol optimization, and proposes workflows that enable scientists to quickly incorporate CRISPR technologies into their research.
  • Demand Assessment Research: adopting insights from behavioural economics
    Demand Assessment Research: adopting insights from behavioural economics Duncan Munro and Andrew McConaghie Recorded: Nov 16 2016 52 mins
    Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world.
    This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the application of this important tool in pharmaceutical market research.
    The masterclass will:
    •Introduce demand assessment research and why it is important to healthcare market research
    •Discuss how insights from behavioural economics can improve quantitative demand assessment market research
    •Highlight a range of techniques using behavioural economics that help you build a more accurate picture of your customers and market.
  • H&E and PAS Troubleshooting and Technical Advice
    H&E and PAS Troubleshooting and Technical Advice Ute Schmidt- Global Product Manager Microscopy at Merck Recorded: Nov 14 2016 62 mins
    H&E is the most frequently used stain in histology and is the basis for diagnostics and further selected methods. Thus it is important to have brilliant staining. We will show which minor factors can give a negative effect or spoil the result completely. Tips will be given on improving the sensitivity of the stain. For PAS, we will give advice on how to avoid common errors and always get colourful results.
    We will discuss:
    •Troubleshooting
    •Technical tricks
    •How to prevent "critical situations"
  • New Guava and Muse Algae Kits for Flow Cytometry
    New Guava and Muse Algae Kits for Flow Cytometry Katherine Gillis- Sr. Research Scientist at MilliporeSigma Recorded: Nov 2 2016 39 mins
    In research areas such as academic, biofuel, food and pharmaceutical industries the determination of algal viability, lipid content, and cell concentration is important in the selection, monitoring, and maintenance of algal cultures. Flow cytometry has been shown to be an ideal method to assess health and lipid content of cultures but has been challenging to adopt due to high complexity and cost of traditional technologies. In this webinar, we present novel simplified methods for algal characterization using microcapillary cytometry on either a simple touch screen based cytometer, the Muse® Cell Analyzer, or a higher throughput cytometric platform, the compact Guava® easyCyte platforms. The MilliporeSigma algae kits utilize simple mix and read protocols, dedicated software modules, and provide quick results for the of count and viability measurements or relative lipid content on algae strains. The optimized and dedicated algae kits allow for high precision and comparable results to predicate methods. Data from applications to multiple common algal strains such as Chlorella vulgaris and Chlamydomonas reinhardti under different culture conditions will be presented. Availability of dedicated kits for algae research on simple and easy to use cytometric platforms will empower and enable algae researchers to rapidly select optimal culture conditions and strains for downstream experiments.
  • Multispectral Imaging Flow Cytometry: Illuminating T cell – APC Interactions
    Multispectral Imaging Flow Cytometry: Illuminating T cell – APC Interactions Haley R. Pugsley, Ph.D, Senior Scientist at MilliporeSigma Recorded: Oct 5 2016 56 mins
    Interaction between antigen-specific T cells and antigen presenting cells (APC) cognate ligand involve reorganization of the cytoskeleton and recruitment of adhesive and signaling molecules to the site of intercellular contact. Sustained adhesion of T cells to APCs and formation of the immunological synapse after T cell receptor stimulation are required for the antigen-specific response. One way to measure an immunological synapse is by fluorescently labeling the molecules that have been recruited to the synapse and imaging by fluorescence microscopy. However, immunological synapses are rare and therefore difficult to analyze objectively and statistically by traditional microscopy methods. To overcome these problems, we employed the Amnis brand imaging flow cytometers to objectively collect imagery of large numbers of cells. We report the percentage of T cells involved in an organized immunological synapse, the recruitment of adhesion molecule LFA-1 and signaling molecule Lck to the synaptic complex and subsequent translocation of NFkB from the cytoplasm to the nucleus in the T cell. In this study, Raji B cells loaded with Staphylococcal enterotoxin B (SEB) were incubated with human T cells to create T cell-APC conjugates. Cells were stained in various combinations for CD3, CD19, Actin, LFA-1, Lck and NFkB. Results from the FlowSight and the ImageStream imaging flow cytometers are compared. Using the FlowSight imaging flow cytometer we demonstrate image-based parameters that were used to assess the frequency of conjugates with an organized immunological synapse in an objective and statistically significant manner. Employing the ImageStream imaging flow cytometer we further evaluate the specific location of the adhesion and signaling molecules LFA-1 and Lck within the immunological synapse complex in T cells and measure the nuclear localization of NFkB in the T cell.
  • Quantitative Image Analysis and Emerging Applications on the ImageStream
    Quantitative Image Analysis and Emerging Applications on the ImageStream Brian Hall, Senior Scientist at Millipore Sigma Recorded: Sep 21 2016 56 mins
    The ImageStream® and FlowSight® are multispectral imaging flow cytometers that generates high resolution images of cells at a rate of 1000’s of cells per second. This allows for the rapid acquisition of tens of thousands of images per sample. Using the IDEAS® image analysis software, the system calculates features based not only on fluorescence intensity but the morphology of that fluorescence as well. This novel approach is able to seamlessly combine the quantitative power of flow cytometry with the high content information associated with microscopy. The system can collect data on a wide range of applications including nuclear localization during a signal transduction cascade, measuring colocalization of two probes, or quantify features on the phagocytosed particles in macrophages.
  • Getting closer to your customer through video technology
    Getting closer to your customer through video technology Damian Eade, Tim Williams, Andrew McConaghie Recorded: Sep 14 2016 61 mins
    Video content accounted for 64% of all the world’s internet traffic in 2014 and is expected to grow to 80% by 2019. As the way in which we connect and digest information evolves, high quality mobile video capture and advanced digital analysis offers ever more authentic, intimate and rich insights into the customers’ world. This webinar will focus on:
    – How emerging technology can enable us to realise the true value of ‘video data’ in our analysis and beyond
    – How mobile technology can be used to get you closer to your customers and their real world experiences right from the earliest stages in product development
    – How real world video content can engage your key stakeholders and ensure customer insights drive action
  • Measuring the cost of the right interventions in diabetes
    Measuring the cost of the right interventions in diabetes John Grumitt, IDF/Diabetes UK, Prof Michael Trenell, Newcastle University, Dr Phil McEwan Recorded: Sep 8 2016 69 mins
    Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.

    This webinar will explore the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.
  • Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes
    Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes Malcolm Qualie, NHS England, Nina Pinwill, NICE, Katie Pascoe, ABPI, Angela McFarlane, IMS Health Toby Gosden, IMS Health Recorded: Aug 2 2016 69 mins
    Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.

    To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement.

    How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via the reformed cancer drugs fund?
  • What do the upcoming changes to England's pharmacy funding mean?
    What do the upcoming changes to England's pharmacy funding mean? John Smith, PAGB, Rob Darracott, Pharmacy Voice, Sandra Gidley, English Pharmacy Board Recorded: Jul 21 2016 67 mins
    New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure.

    UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community? How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?

    Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change. Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
  • Multichannel Maturometer 2016 results: Key global trends
    Multichannel Maturometer 2016 results: Key global trends Ruud Kooi ( VP Business Development, Across Health), Dirk Szynka (MD, Across Health Germany) Recorded: Jul 14 2016 39 mins
    Key topics:

    - Digital maturity of pharma
    - Hot trends in multichannel marketing
    - Evolution of digital budgets
    - Key barriers
  • BREXIT: What's next for pharma?
    BREXIT: What's next for pharma? Stephen Dorrell, Chair NHS Confederation, Leslie Galloway, EMIG, Prof. Mike Bewick, prev NHS England, Dr Rick Greville, ABPI Recorded: Jul 14 2016 71 mins
    The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.

    Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?

    In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:

    The impact of Brexit on UK Healthcare
    The ramification of Brexit for pharma in the UK
    What does the Brexit scenario mean for global pharma?
  • Establishing a Solid Foundation for Digital Transformation
    Establishing a Solid Foundation for Digital Transformation Alexandre Gultzgoff, Deputy Director, IT, Sanofi Pasteur MSD Antoine Blanc, Commercial Excellence Director, Sanofi Pasteur MS Recorded: Jul 12 2016 63 mins
    Sanofi Pasteur MSD is transforming its commercial organisation and remodeling its approach to customer engagement. Hear from Sanofi Pasteur MSD’s Alexandre Gultzgoff, Deputy Director, IT, and Antoine Blanc, Commercial Excellence Director, as they share first hand insights on how they are transforming their European commercial operations and improving customer engagement. Learn from their best practice as they share Sanofi Pasteur MSD’s:
    · Vision and strategy for digital transformation
    · Digital channels (CLM, email) to improve customer engagement
    · Deployment of a digital supply chain in ensuring fresh content to channels and content reuse
  • What's next for patient-centricity? How do we know when we are patient-centric?
    What's next for patient-centricity? How do we know when we are patient-centric? Jo Fearnhead-Wymbs, Ashfield Healthcare, Anita Osborn, Ashfield Clinical, Andrew Schorr, Patient Power, Paul Robinson, MS Recorded: Jul 5 2016 63 mins
    This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric? How should they measure the impact of their strategy through the lifecycle of a drug and their business as a whole?
  • New Methods for Flow WBC Differential
    New Methods for Flow WBC Differential Dr. Francis Lacombe, M.D., Ph.D., Université Hôpital, Haut-Lévêque, Pessac, France Recorded: Jun 29 2016 61 mins
    Join Francis Lacombe, M.D., Ph.D., head of the hematology/automation laboratory and director of flow cytometry at the Université Hôpital, Haut-Lévêque, Pessac, France, to learn how Beckman Coulter’s HematoFlow* and CytoDiff* were instrumental to a recent study that tracked blast decrease rate in acute myeloid leukemia (AML) patients.
  • Life sciences promotional content management for speed, compliance and insight
    Life sciences promotional content management for speed, compliance and insight David Bennett, Andrew McConaghie Apr 27 2017 9:00 am UTC 75 mins
    The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.

    Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.

    Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.

    From this webinar you will:

    – Learn the current state of commercial content and digital asset management in life sciences promotions
    – Garner an understanding of how your organization compares to the industry
    – Understand how to accelerate your content across the digital supply chain
  • Sample Preparation for Food Analysis:  New Technologies and Techniques
    Sample Preparation for Food Analysis: New Technologies and Techniques Jennifer Claus, Product Manager, Franchise Marketing Sample Preparation (Non-Bio) Apr 27 2017 1:00 pm UTC 75 mins
    In typical analytical workflows, sample preparation accounts for over 60% of the time taken to generate results and 30% of any errors generated. To help analytical chemists maintain the cornerstones of all analytical processes, namely; speed, specificity, sensitivity, and reproducibility, considerable resources have been devoted to the development of new and unique technologies in the sample preparation field. With specific reference to solid phase extraction and solid phase microextraction, this presentation will outline new technologies and techniques developed in sample preparation for food analysis.
  • The future of the clinical trial – collaboration and patient centricity
    The future of the clinical trial – collaboration and patient centricity Jameisha Brown, Eric Delente, Paulo Moreira, Christine Phillips, Andrew McConaghie May 3 2017 1:00 pm UTC 75 mins
    Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.

    With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.

    To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
  • Lung Cancer and IHC
    Lung Cancer and IHC Jeff Gordon, Cell Marque- Rocklin, CA May 12 2017 3:00 pm UTC 75 mins
    Lung cancer is the most commonly diagnosed non-skin cancer in the United States. Each year, over 222,000 people are diagnosed with lung cancer, and over 150,000 succumb each year to the illness, making it also the deadliest cancer in the country. With constant advancement of treatment options, the importance of accurate diagnosis and detection of lung cancer becomes more and more relevant to the survival of the patient. Immunohistochemistry has served as the catalyst for these advancements in lung cancer diagnosis. This presentation covers many of the basic science, facts, and statistics of lung cancer, as well as the utility of immunohistochemical testing with markers such as TTF-1, napsin A, desmoglein-3, and p40 in the accurate diagnosis and survival rates of lung cancer.
  • Multichannel Rep
    Multichannel Rep Annelien Van Boxlaer (VP Innovation Strategy, Across Health) & Patrick Vidal (MD, Across Health France) May 30 2017 3:00 pm UTC 60 mins
    The world of the field force is changing. Increased digitalisation, powerful new tools and a growing expectation that they ‘conduct’ multiple channels means new skills, ways of working, and even thinking, are needed.

    This shift will radically change the structure of the traditional Pharma organization. Differences between HQ and local offices will become less pronounced as the field force gains the ability to deploy highly tailored, right-on-time content, in the best possible format for individual physicians.

    Find out more about how the time of the Multichannel Rep is now, how upskilling and reskilling are the buzzwords for new engagement models, and how not to have your field force being left behind in the digital race!

    Topics include:
    •Getting the right digital tools into the hands of reps
    •How to evaluate what the best channels for your situation are
    •Finding out what good looks like
    •How to engage your field force, manage the change, and sustain their motivation
  • Basic Principles of Solid Phase Microextraction (SPME) Method Development
    Basic Principles of Solid Phase Microextraction (SPME) Method Development Emanuela Gionfriddo, Ph.D.; Research Associate under Prof. Janusz Pawliszyn, University of Waterloo (ON, Canada) May 31 2017 1:30 pm UTC 75 mins
    For the past two decades, Solid Phase Microextraction (SPME) has represented a convenient alternative to conventional sample prep procedures. SPME allows the simultaneous extraction and enrichment of analytes of interest from a given matrix in a single step while avoiding, or drastically minimizing, the use of organic solvents and time-consuming cleanup procedures.
    Like any other analytical method, the various parameters governing the SPME process need to be carefully optimized in order to achieve robustness and sensitivity. However, certain aspects of SPME method development are often overlooked by many users, leading to unsatisfactory performance of the technique.
    This webinar will shed light into several aspects of SPME method development. The presentation will include a theoretical explanation of SPME fundamentals and practical suggestions to overcome common errors and bias encountered when using SPME.
    The webinar is divided in three main sections: 1) optimization of extraction conditions 2) matrix modifications 3) optimization of desorption conditions for gas and liquid chromatography. Each section is divided in various subsections dedicated to each parameter affecting the performance of the SPME technique. The webinar attendees will be guided through comprehensive understanding of the technology and the critical parameters that influence the extraction process with practical examples from already existing methods.